Workflow
Boundless Bio Reports Second Quarter 2025 Financial Results and Business Highlights
Boundless Bio, Inc.Boundless Bio, Inc.(US:BOLD) GlobeNewswire News Room·2025-08-05 11:00

Core Insights - Boundless Bio is advancing its clinical programs targeting oncogene-amplified cancers, specifically through the BBI-355 and BBI-825 combination in the POTENTIATE trial, which is now open for enrollment [1][7] - The company is on track to submit an investigational new drug (IND) application for BBI-940 in the first half of 2026, aiming to deliver initial proof-of-concept clinical data within its existing cash runway timeline [1][7] - As of June 30, 2025, Boundless Bio has $127 million in cash, which is expected to support operations into the first half of 2028 [1][7] Research and Development Highlights - The POTENTIATE clinical trial is focused on evaluating the combination of BBI-355, a selective CHK1 inhibitor, and BBI-825, a selective RNR inhibitor, for their synergistic anti-tumor activity [5][7] - BBI-940 is being developed as a first-in-class orally bioavailable selective Kinesin degrader, with IND-enabling studies currently underway [5][7] Financial Performance - For the second quarter of 2025, research and development expenses were $12.2 million, a decrease from $14.7 million in the same period of 2024 [7][9] - General and administrative expenses were $4.8 million for the second quarter of 2025, slightly up from $4.7 million in the same period of 2024 [7][9] - The net loss for the second quarter of 2025 was $15.7 million, compared to a net loss of $17.0 million for the same period in 2024 [7][9]